埃罗替尼在非小细胞肺癌治疗中的研究进展

Erlotinib in the treatment of non-small cell lung cancer

埃罗替尼（erlotinib）是表皮生长因子受体（EGFR）酪氨酸激酶抑制剂，能与细胞内EGFR分子酪氨酸激酶结构域的ATP结合袋特异性结合，可逆性地抑制EGFR酪氨酸激酶活性，促使肿瘤细胞凋亡，抑制肿瘤细胞的增殖、侵袭、血管新生和转移。该药目前已成功用于晚期非小细胞肺癌（NSCLC）的治疗，可显著延长患者的生存时间和无进展生存时间，显著改善症状，改善患者生活质量。

Erlotinib is epidermal growth factor receptor（EGFR） tyrosine kinase inhibitor that compete for the ATP-binding pocket of EGFR tyrosine kinase in the cytoplasmic tail. Erlotinib inhibits the activity of EGFR tyrosine kinase reversibly, thus induces tumor cells apopotosis, inhibits cellular proliferation, angiogenesis, tumor invasion, and metastasis, Erlotinib can prolong overall survival and progress free survival in patients with advanced non-small-cell lung cancer, relieve symptoms and improve quality of life.